Charles River Labs to Present at J.P. Morgan Conference and Announce Acquisitions

Details

announced that it will present at the J.P. Morgan 44th Annual Healthcare Conference on January 13, 2026. The company reported improved demand trends in its Discovery and Safety Assessment (DSA) business with a preliminary DSA net book-to-bill of approximately 1.1x in Q4 2025. Charles River also plans to acquire K.F. (Cambodia) Ltd. and PathoQuest SAS to vertically integrate its DSA supply operations and expand its Biologics Testing business.

Items reported

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. provides essential services to the pharmaceutical, biotechnology, and life sciences industries. The company specializes in preclinical and clinical lab services, offering clients a comprehensive suite of drug discovery and development services that expedite the process of getting new drugs and therapies to the market. Notably, Charles River's facilities offer expertise in the fields of oncology, immunology, and neuroscience, making it a critical partner for companies working in these therapeutic areas. The firm operates globally, enhancing its customers' ability to operate internationally through its wide network of laboratories and testing facilities. By enabling more efficient drug development cycles and reducing the time to market for new therapies, Charles River Laboratories plays a crucial role in the advancement of medical science and patient care worldwide. The company's commitment to high standards of animal welfare and ethical practices further underscores its reputation as a leader in quality and reliability within the research community.